Clinical Patterns of Traditional Chinese Medicine for Ischemic Heart Disease Treatment: A Population-Based Cohort Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE
    • Publication Information:
      Publication: 2018- : Basel, Switzerland : MDPI
      Original Publication: Kaunas : Lietuvos gydytojų sąjunga
    • Subject Terms:
    • Abstract:
      Background and objectives: Traditional Chinese medicines (TCMs) are widely prescribed to relieve ischemic heart disease (IHD); however, no cohort studies have been conducted on the use of TCMs for patients with IHD. The aim of the study was to analyze TCM prescription patterns for patients with IHD. Materials and Methods: The retrospective population-based study employed a randomly sampled cohort of 4317 subjects who visited TCM clinics. Data were obtained from the National Health Insurance Research Database (NHIRD) of Taiwan for the period covering 2000 to 2017. Data analysis focused on the top ten most commonly prescribed formulae and single TCMs. We also examined the most common two- and three-drug combinations of TCM in single prescriptions. Demographic characteristics included age and sex distributions. Analysis was performed on 22,441 prescriptions. Results: The majority of TCM patients were male (53.6%) and over 50 years of age (65.1%). Zhi-Gan-Cao-Tang (24.76%) was the most frequently prescribed formulae, and Danshen (28.89%) was the most frequently prescribed single TCM for the treatment of IHD. The most common two- and three-drug TCM combinations were Xue-Fu-Zhu-Yu-Tang and Danshen" (7.51%) and "Zhi-Gan-Cao-Tang, Yang-Xin-Tang, and Gua-Lou-Xie-Bai-Ban-Xia-Tang" (2.79%). Conclusions: Our results suggest that most of the frequently prescribed TCMs for IHD were Qi toning agents that deal with cardiovascular disease through the promotion of blood circulation. The widespread use of these drugs warrants large-scale, randomized clinical trials to investigate their effectiveness and safety.
    • References:
      Medicines (Basel). 2018 May 21;5(2):. (PMID: 29883402)
      Biomed Pharmacother. 2022 Jan;145:112450. (PMID: 34839257)
      J Ethnopharmacol. 2014 Oct 28;156:190-8. (PMID: 25178948)
      Oxid Med Cell Longev. 2019 Feb 24;2019:3231424. (PMID: 30918578)
      Phytomedicine. 2021 Oct;91:153694. (PMID: 34403879)
      Front Pharmacol. 2010 Aug 24;1:111. (PMID: 21607062)
      Complement Ther Med. 2019 Dec;47:102203. (PMID: 31779994)
      J Mol Cell Cardiol. 2019 Dec;137:59-70. (PMID: 31629735)
      Int Immunopharmacol. 2020 Dec;89(Pt B):107086. (PMID: 33068868)
      J Ethnopharmacol. 2019 Apr 24;234:68-75. (PMID: 30268652)
      Singapore Med J. 2015 Jan;56(1):11-8. (PMID: 25640094)
      Acta Pharmacol Sin. 2011 Feb;32(2):141-51. (PMID: 21293466)
      Sci Rep. 2020 Oct 20;10(1):17787. (PMID: 33082379)
      Evid Based Complement Alternat Med. 2019 Jun 23;2019:9107847. (PMID: 31341503)
      Chem Biol Drug Des. 2014 Nov;84(5):513-21. (PMID: 24725674)
      Curr Drug Metab. 2019;20(9):701-713. (PMID: 31453781)
      J Cardiovasc Pharmacol. 2014 Jul;64(1):28-37. (PMID: 24621647)
      Curr Pharm Des. 2017;23(7):1077-1097. (PMID: 27748194)
      Phytother Res. 2014 Jul;28(7):961-75. (PMID: 24339367)
      Evid Based Complement Alternat Med. 2012;2012:716459. (PMID: 22454677)
      Int J Cardiol. 2017 Feb 1;228:90-96. (PMID: 27863367)
      J Ethnopharmacol. 2019 Sep 15;241:112010. (PMID: 31175928)
      BMC Complement Altern Med. 2016 Feb 06;16:56. (PMID: 26852136)
      Front Pharmacol. 2018 Jul 09;9:736. (PMID: 30038572)
      Acta Pharmacol Sin. 2010 May;31(5):546-53. (PMID: 20418897)
      J Ethnopharmacol. 2021 Dec 5;281:114438. (PMID: 34390798)
      Chem Pharm Bull (Tokyo). 2004 Nov;52(11):1295-301. (PMID: 15516749)
      J Ethnopharmacol. 2014;151(1):218-27. (PMID: 24189032)
      Oncotarget. 2017 Feb 28;8(9):15470-15489. (PMID: 28099940)
      Drug Des Devel Ther. 2020 Sep 15;14:3731-3746. (PMID: 32982178)
      Gend Med. 2008;5 Suppl A:S76-90. (PMID: 18395685)
      Front Pharmacol. 2020 Dec 11;11:579332. (PMID: 33536906)
      Acta Pharmacol Sin. 2018 May;39(5):802-824. (PMID: 29698387)
      Eur J Clin Nutr. 2015 Jan;69(1):134-42. (PMID: 25369831)
      Heart Views. 2017 Jul-Sep;18(3):109-114. (PMID: 29184622)
      Atherosclerosis. 2012 Jan;220(1):3-10. (PMID: 21774934)
      Adv Pharmacol. 2020;87:43-70. (PMID: 32089238)
      Zhongguo Zhong Yao Za Zhi. 2015 Jun;40(11):2174-9. (PMID: 26552176)
      J Chromatogr A. 2009 Mar 13;1216(11):2063-70. (PMID: 18394634)
      BMC Complement Altern Med. 2013 Aug 15;13:209. (PMID: 23947955)
      Evid Based Complement Alternat Med. 2014;2014:267976. (PMID: 25525444)
      J Ethnopharmacol. 2015 Sep 15;173:370-82. (PMID: 26239152)
      Zhong Yao Cai. 2005 Oct;28(10):920-2. (PMID: 16479932)
      Front Pharmacol. 2020 Jul 30;11:1170. (PMID: 32848777)
      Complement Ther Med. 2015 Apr;23(2):251-6. (PMID: 25847563)
      Eur J Med Chem. 2018 Mar 10;147:150-162. (PMID: 29432947)
      Acta Pharmacol Sin. 2022 Jun;43(6):1408-1418. (PMID: 34552216)
      Pharm Biol. 2016 Dec;54(12):3226-3231. (PMID: 27687158)
      Zhongguo Zhong Yao Za Zhi. 2016 Oct;41(20):3721-3726. (PMID: 28929647)
      J Tradit Chin Med. 2011 Dec;31(4):338-43. (PMID: 22462242)
      Expert Opin Ther Pat. 2013 Feb;23(2):149-53. (PMID: 23231009)
      Biomed Pharmacother. 2020 Nov;131:110734. (PMID: 32942158)
      J Pharm Biomed Anal. 2014 Jan;88:225-34. (PMID: 24080525)
      Eur Heart J. 2018 Sep 7;39(34):3165-3241. (PMID: 30165544)
      PLoS One. 2012;7(6):e38627. (PMID: 22715398)
      J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175)
      J Pharm Pharmacol. 2000 Nov;52(11):1387-93. (PMID: 11186247)
      J Clin Pharmacol. 2005 Dec;45(12):1345-59. (PMID: 16291709)
      J Immunol Res. 2017;2017:3780572. (PMID: 29250558)
      Chin J Nat Med. 2021 Mar;19(3):161-169. (PMID: 33781449)
      Medicine (Baltimore). 2017 May;96(21):e6998. (PMID: 28538412)
      Biopharm Drug Dispos. 2017 Jan;38(1):33-49. (PMID: 27925234)
    • Grant Information:
      MOST 109-2320-B-037-024-MY3 Ministry of Science and Technology of Taiwan
    • Contributed Indexing:
      Keywords: Taiwan; ischemic heart disease; national health insurance database; prescribing patterns; traditional Chinese medicine
    • Accession Number:
      0 (Drug Combinations)
    • Publication Date:
      Date Created: 20220727 Date Completed: 20220728 Latest Revision: 20220731
    • Publication Date:
      20240105
    • Accession Number:
      PMC9320598
    • Accession Number:
      10.3390/medicina58070879
    • Accession Number:
      35888597